Biological Products, Except Diagnostic Substances (Biotech) - Insider Trading Data

Insiders are officers, directors, or significant investors. This page shows insider sentiment and transactions for the Biological industry. Research shows that insider trades are predictive of future stock returns. By examining insider trades for an industry, we can understand what well-informed people think of the overall future industry prospects.

Biological Products, Except Diagnostic Substances (Biotech) - Insider Buy/Sell Ratio

Insider selling and buying is a useful indicator for analyzing the market because it serves as a proxy for their optimism or pessimism in their own companies. By looking at ratio of total selling and buying across the entire market, we might be able to draw some conclusions about the future market.

We offer two charts here. The first one shows the total dollar volume of buying and selling by insiders. The second chart shows the ratio of the number of insiders selling, vs. the number of insiders buying. In both charts, we filter out trades made by indirect holders (such as trusts), and 10% owners (who, although considered an 'insider' by the SEC, do not actually manage the companies in which they are considered insiders).

Corporate Insider Buy Sell Ratio (Dollar Volume) - Biological Products, Except Diagnostic Substances (Biotech)
Corporate Insider Buy Sell Ratio (Insider Count) - Biological Products, Except Diagnostic Substances (Biotech)
Biological Products, Except Diagnostic Substances (Biotech) - Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b5-1 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Security Form Insider Code 10b5-1 Direct Share
Price
Shares
Changed
2026-04-01 TARA / Protara Therapeutics, Inc. 4 Zummo Jacqueline S - Sale D 5.26 -22,598
2026-04-01 KYMR / Kymera Therapeutics, Inc. 4 Chadwick Jeremy G S - Sale D 85.4144 -13,540
2026-04-01 VIR / Vir Biotechnology, Inc. 4 SATO VICKI L S - Sale D 9.0735 -22,000
2026-04-01 TWST / Twist Bioscience Corporation 4 Starovasnik Melissa A. S - Sale D 51.00 -1,000
2026-04-01 CGEN / Compugen Ltd. 4 Levine Zurit S - Sale D 2.20 -3,500
2026-04-01 BEAM / Beam Therapeutics Inc. 4 Ciaramella Giuseppe S - Sale D 24.58 -11,810
2026-04-01 BEAM / Beam Therapeutics Inc. 4 Cavanagh Bethany J S - Sale D 24.58 -3,242
2026-04-01 CGEN / Compugen Ltd. 4 Ophir Eran S - Sale D 2.2067 -5,625
2026-04-01 FENC / Fennec Pharmaceuticals Inc. 4 Raykov Rosty S - Sale D 6.31 -10,946
2026-04-01 HALO / Halozyme Therapeutics, Inc. 4 Torley Helen S - Sale D 65.714 -1,000
2026-04-01 BEAM / Beam Therapeutics Inc. 4 Bellon Christine S - Sale D 24.58 -5,956
2026-04-01 APGE / Apogee Therapeutics, Inc. 4 Dambkowski Carl S - Sale D 85.89 -100
2026-04-01 APGE / Apogee Therapeutics, Inc. 4 Henderson Jane S - Sale D 85.46 -1,100
2026-04-01 HALO / Halozyme Therapeutics, Inc. 4 Torley Helen S - Sale D 65.358 -19,000
2026-04-01 APGE / Apogee Therapeutics, Inc. 4 Dambkowski Carl S - Sale D 85.33 -2,702
2026-04-01 APGE / Apogee Therapeutics, Inc. 4 Henderson Jane S - Sale D 84.46 -900
2026-04-01 APGE / Apogee Therapeutics, Inc. 4 Dambkowski Carl S - Sale D 84.31 -2,698
2026-04-01 CGEN / Compugen Ltd. 4 Levine Zurit M - Exercise D 1.15 1,000
2026-04-01 CGEN / Compugen Ltd. 4 Levine Zurit M - Exercise D 0.8292 2,500
2026-04-01 HALO / Halozyme Therapeutics, Inc. 4 Torley Helen M - Exercise D 12.07 20,000
2026-04-01 OCGN / Ocugen, Inc. 4 Zhang Junge M - Exercise D 0.46 112,205
2026-04-01 APGE / Apogee Therapeutics, Inc. 4 Dambkowski Carl M - Exercise D 22.86 4,125
2026-04-01 OCGN / Ocugen, Inc. 4 Zhang Junge M - Exercise D 0.51 15,000
2026-04-01 FENC / Fennec Pharmaceuticals Inc. 4 Raykov Rosty M - Exercise D 2.45 15,598
2026-04-01 OCGN / Ocugen, Inc. 4 Zhang Junge M - Exercise D 1.42 66,929
2026-04-01 KYMR / Kymera Therapeutics, Inc. 4 Chadwick Jeremy G M - Exercise D 29.64 14,640
2026-04-01 KYMR / Kymera Therapeutics, Inc. 4 Ridloff Elena M - Exercise D 14.18 4,600
2026-04-01 BIIB / Biogen Inc. 4 Godbout Sean M - Exercise D 181
2026-04-01 ADPT / Adaptive Biotechnologies Corporation 4 RUBINSTEIN JULIE M - Exercise D 7.27 14,722
2026-04-01 IMVT / Immunovant, Inc. 4 Venker Eric M - Exercise D 14.46 368,750
2026-04-01 CGEN / Compugen Ltd. 4 Ophir Eran M - Exercise D 0.8292 5,625
2026-04-01 ADMA / ADMA Biologics, Inc. 4 Kestenberg-Messina Kaitlin M. F - Taxes D 9.11 -20,362
2026-04-01 IPSC / Century Therapeutics, Inc. 4 Cowan Chad F - Taxes D 2.19 -1,365
2026-04-01 BIIB / Biogen Inc. 4 Godbout Sean F - Taxes D 183.78 -54
2026-04-01 IMVT / Immunovant, Inc. 4 Venker Eric D - Sale to Issuer D 25.10 -334,960
2026-04-01 REPL / Replimune Group, Inc. 4 Schwendenman Andrew A - Award D -36,667
2026-04-01 VYGR / Voyager Therapeutics, Inc. 4 Shiferman Gregory L. A - Award D 50,000
2026-04-01 REPL / Replimune Group, Inc. 4 Sarchi Christopher A - Award D 50,000
2026-04-01 REPL / Replimune Group, Inc. 4 Astley-Sparke Philip A - Award D 50,000
2026-04-01 REPL / Replimune Group, Inc. 4 Xynos Konstantinos A - Award D 50,000
2026-04-01 REPL / Replimune Group, Inc. 4 Patel Sushil A - Award D 251,240
2026-04-01 CCCC / C4 Therapeutics, Inc. 4 GROGAN DONNA ROY A - Award D 2.70 5,370
2026-04-01 AGEN / Agenus Inc. 4 HARRISON THOMAS L A - Award D 3.319 9,228
2026-04-01 CCCC / C4 Therapeutics, Inc. 4 Anderson Kenneth Carl A - Award D 2.70 4,259
2026-04-01 RXRX / Recursion Pharmaceuticals, Inc. 4 Li Dean Y A - Award D 3,268
2026-04-01 REPL / Replimune Group, Inc. 4 Hill Emily Luisa A - Award D 50,000
2026-04-01 RXRX / Recursion Pharmaceuticals, Inc. 4 Dar Zavain A - Award D 4,902
2026-03-31 ALLO / Allogene Therapeutics, Inc. 4 Beneski Benjamin Machinas S - Sale D 2.50 -2,867
2026-03-31 BEAM / Beam Therapeutics Inc. 4 Evans John M. S - Sale D 22.7634 -25,000
2026-03-31 KYMR / Kymera Therapeutics, Inc. 4 Chadwick Jeremy G S - Sale D 85.3792 -7,600
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)